Clinical research of microwave ablation plus sorafenib in the treatment of advanced-stage hepatocellular carcinoma
10.3760/cma.j.issn.1673-422X.2016.04.005
- VernacularTitle:微波消融术联合索拉非尼治疗晚期肝细胞癌的临床研究
- Author:
Yafei ZHANG
;
Lijun SHENG
;
Yahong SUN
;
Pengyuan SONG
;
Guohua REN
;
Yuji AN
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Microwaves;
Sorafenib
- From:
Journal of International Oncology
2016;43(4):258-261
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical effects and adverse effects of microwave ablation (MWA) with sorafenib and sorafenib monotherapy in the treatment of advanced-stage hepatocellular carcinoma (HCC).Methods Medical records and follow-up information of 57 patients with advanced-stage HCC were retrospectively reviewed.25 patients were treated with MWA combined with sorafenib (combined group),and 32 patients were treated with sorafenib monotherapy (monotherapy group).The end points were therapeutic effect,progression-free survival (PFS),overall survival (OS) and adverse reactions.Results The objective response rate in the combined group was similar to the monotherapy group (16.0％ vs.3.1％,x2 =1.521,P =0.217).The disease control rate in the combined group was significantly higher than that in the monotherapy group (80.0％ vs.50.0％,χ2 =5.429,P =0.020).The median PFS in the combined group was longer than that in the monotherapy group (6.0 months vs.3.2 months,x2 =7.675,P =0.006),but the median OS was similar (11.5 months vs.8.5 months,x2 =2.480,P =0.115).The serious adverse reactions were similar between the two treatment groups (44.0％ vs.34.4％,x2 =0.549,P =0.459).Conclusion MWA plus sorafenib is superior to sorafenib alone with respect to PFS in patients with advanced-stage HCC,although it may not improve OS,with no increased risk of serious adverse reactions.
